ACR Appropriateness Criteria s Advanced Stage Endometrial Cancer
暂无分享,去创建一个
B. Erickson | W. Yuh | S. Jolly | W. Small | N. Mayr | H. Cárdenes | D. Gaffney | C. Yashar | M. Varia | A. Wolfson | M. Elshaikh | E. Kidd | Larissa J. Lee | A. Jhingran | D. Moore | A. Wahl | G. Rao | L. Lee
[1] R. Barakat,et al. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer. , 2013, Gynecologic oncology.
[2] A. Secord,et al. A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. , 2013, Gynecologic oncology.
[3] W. Small,et al. A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418. , 2012, International journal of radiation oncology, biology, physics.
[4] D. Miller,et al. Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study , 2012 .
[5] L. Levy,et al. Vaginal motion and bladder and rectal volumes during pelvic intensity-modulated radiation therapy after hysterectomy. , 2012, International journal of radiation oncology, biology, physics.
[6] J. Rownd,et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. , 2012, Brachytherapy.
[7] P. Zola,et al. Chemotherapy Plus Radiation in Advanced-Stage Endometrial Cancer , 2011, International Journal of Gynecologic Cancer.
[8] S. Pignata,et al. Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study , 2011, Oncology.
[9] Matthew J. Pearson,et al. A Phase I Study using low-dose fractionated whole abdominal radiotherapy as a chemopotentiator to full-dose cisplatin for optimally debulked stage III/IV carcinoma of the endometrium. , 2011, Gynecologic oncology.
[10] B. Goff,et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. , 2011, American journal of obstetrics and gynecology.
[11] L. Downs,et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. , 2011, Gynecologic oncology.
[12] Jason D. Wright,et al. Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. , 2011, Obstetrics and gynecology.
[13] P. Zola,et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. , 2010, European journal of cancer.
[14] K. Dusenbery,et al. A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinoma. , 2010, Gynecologic oncology.
[15] H. Putter,et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.
[16] L. Ramondetta,et al. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. , 2009, Gynecologic oncology.
[17] A. Secord,et al. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. , 2009, Gynecologic oncology.
[18] S. Pecorelli. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .
[19] D. Cella,et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. , 2009, Gynecologic oncology.
[20] P. Grigsby,et al. Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation. , 2009, Gynecologic oncology.
[21] Joan L. Walker,et al. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study. , 2009, Gynecologic oncology.
[22] A. Fortin,et al. Clinical outcome of adjuvant treatment of endometrial cancer using aperture-based intensity-modulated radiotherapy. , 2008, International journal of radiation oncology, biology, physics.
[23] M. Einstein,et al. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). , 2008, Gynecologic oncology.
[24] A. Mariani,et al. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. , 2007, Gynecologic oncology.
[25] M. Carey,et al. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach. , 2007, International journal of radiation oncology, biology, physics.
[26] J. Cooper,et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. , 2006, Gynecologic oncology.
[27] P. Zola,et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial , 2006, British Journal of Cancer.
[28] M. Hendrickson,et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers , 2006, British Journal of Cancer.
[29] P. Maisonneuve,et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[30] J. Thigpen,et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Warren D'Souza,et al. Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. , 2005, International journal of radiation oncology, biology, physics.
[32] M. Maiman,et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.
[33] R. Burger,et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] O. Gómez-Marín,et al. Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. , 2004, Gynecologic oncology.
[35] P. Franzone,et al. Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. , 2004, Gynecologic oncology.
[36] R. Broaddus,et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. , 2003, Gynecologic oncology.
[37] John C Roeske,et al. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. , 2003, International journal of radiation oncology, biology, physics.
[38] M. J. Webb,et al. Stage IIIC endometrioid corpus cancer includes distinct subgroups. , 2002, Gynecologic oncology.
[39] John C Roeske,et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. , 2002, International journal of radiation oncology, biology, physics.
[40] A. Mundt,et al. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. , 2001, International journal of radiation oncology, biology, physics.
[41] A. Mundt,et al. Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. , 2001, International journal of radiation oncology, biology, physics.
[42] J. Roeske,et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. , 2000, International journal of radiation oncology, biology, physics.
[43] P. Koper,et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. , 2000 .
[44] G. Sutton,et al. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. , 1999, Gynecologic oncology.
[45] A. Mundt,et al. The significance of adnexal involvement in endometrial carcinoma. , 1999, Gynecologic oncology.
[46] S. Liao,et al. A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: a Gynecologic Oncology Group pilot study. , 1996, Gynecologic oncology.
[47] B. Corn,et al. Pathologic stage III endometrial carcinoma: Significance of extrauterine sites , 1996 .
[48] M. Ranney,et al. Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.